Furthermore, the fusion oncogene EML4-ALK – an essential growth driver in human cancer – was detected in TEPs from patients with non-small-cell lung cancer (NSCLC) and was proven relevant for prognosis and monitoring of therapy, whilst KLK3, FOLH1, and NPY genes were sequestered in platelets from patients with prostate cancer and enabled prediction of treatment outcomes (114, 115). The gene discussed is EML4; the disease is non-small cell lung carcinoma.